Form 4: Johnson & Johnson Executive James D. Swanson Reports Stock Option and Restricted Share Unit Awards

EVP and CIO of Johnson & Johnson, James D. Swanson, reports the acquisition of stock options and restricted share units under the company's Long-Term Incentive Plan.

Summary

• James D. Swanson, EVP and CIO of Johnson & Johnson, filed a Form 4 detailing changes in beneficial ownership.
• On February 15, 2025, Swanson was awarded 34,476 employee stock options with an exercise price of $156.15.
• These options vest in three equal annual installments starting on the first anniversary of the grant date and expire on 02/15/2035.
• Swanson also received 2,127 restricted share units (RSUs) which also vest in three equal annual installments beginning on the first anniversary of the grant date.
• The RSUs convert into shares of Common Stock on a one-for-one basis upon vesting.
• Following these transactions, Swanson directly owns 34,476 derivative securities and 2,127 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, indicating alignment of management interests with shareholders. There are no red flags or negative implications.

Positives

• The grant of stock options and RSUs aligns Mr. Swanson's interests with those of the shareholders, incentivizing him to drive long-term value for the company.
• The vesting schedule encourages continued service and commitment to Johnson & Johnson over the next three years.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.

Industry Context

Stock option and RSU grants are common practice in executive compensation packages within the pharmaceutical and healthcare industries, aligning executive incentives with shareholder value and company performance.

Comparison to Industry Standards

• Companies like Pfizer (PFE) and Merck (MRK) also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and grant sizes are generally comparable to industry standards for executives at similar levels within large, publicly traded companies.
• The specific terms of these grants, such as the exercise price and vesting period, are determined by the company's compensation committee and are designed to be competitive with those offered by peer companies.

Stakeholder Impact

• Shareholders: The grants align executive interests with shareholder value.
• Employees: The grants are part of the company's overall compensation strategy to attract and retain talent.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Restricted Share Units, JNJ, Johnson & Johnson, Executive Compensation, Long-Term Incentive Plan